GlycorX
Phase 1- Indications
- Type 2 diabetes
Company intelligence / Profile preview
Zephyr Group is developing a portfolio of biotechnology-driven products targeting aging-related diseases and longevity optimization. Their approach combines advanced peptide science with plant-based bioactives and precision medicine tools such as DNA testing. They have patented formulations/products in preclinical or early clinical stages across metabolic disease, pain management, obesity, skincare/cosmeceuticals and mental health indications. No published late-stage clinical results yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zephyr Group, Inc..